{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:29:39Z","timestamp":1793284179101,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.lana.2022.100302","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T05:40:51Z","timestamp":1655962851000},"page":"100302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: A nested case-control study"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-5237","authenticated-orcid":false,"given":"Abisola","family":"Olopoenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Camelo-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danya M.","family":"Qato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adepeju","family":"Adekoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Sera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Simoni-Wastila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2022.100302_bib0001","series-title":"Overdose Death Rates | National Institute on Drug Abuse","year":"2021"},{"key":"10.1016\/j.lana.2022.100302_bib0002","article-title":"Drug overdose deaths in the United States, 1999\u20132019","volume":"394","author":"Hedegaard","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"11","key":"10.1016\/j.lana.2022.100302_bib0003","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths \u2014 United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lana.2022.100302_bib0004","series-title":"Information Sheet on Opioid Overdose [Internet]","year":"2014"},{"key":"10.1016\/j.lana.2022.100302_bib0005","series-title":"Concurrent Use of Opioids and Benzodiazepines in a Medicare Part D Population","year":"2016"},{"key":"10.1016\/j.lana.2022.100302_bib0006","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis: Sun EC, Dixit A, Humphreys K, et\u00a0al","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.lana.2022.100302_bib0007","article-title":"Exposure Response Association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in medicare part D beneficiaries","volume":"1","author":"Hernandez Immaculada","year":"2018","journal-title":"JAMA"},{"issue":"8012","key":"10.1016\/j.lana.2022.100302_bib0008","first-page":"1","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study","volume":"350","author":"Saitz","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.lana.2022.100302_bib0009","unstructured":"Cdc.gov.https:\/\/www.cdc.gov\/nchs\/data\/nhsr\/nhsr137-508.pdf. Published 2021. Accessed 10 September 2021."},{"key":"10.1016\/j.lana.2022.100302_bib0010","series-title":"Benzodiazepines and Opioids|National Institute on Drug Abuse","year":"2021"},{"issue":"3","key":"10.1016\/j.lana.2022.100302_bib0011","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamasurg.2016.4952","article-title":"Enhanced recovery after surgery: a review","volume":"152","author":"Ljungqvist","year":"2017","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.lana.2022.100302_bib0012","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clnu.2010.01.004","article-title":"The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials","volume":"29","author":"Varadhan","year":"2010","journal-title":"Clin Nutr"},{"key":"10.1016\/j.lana.2022.100302_bib0013","article-title":"Gabapentin for off-label use: evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst Abuse"},{"key":"10.1016\/j.lana.2022.100302_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front Psychiatry"},{"issue":"7","key":"10.1016\/j.lana.2022.100302_bib0015","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.lana.2022.100302_bib0016","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/10550490601186238","article-title":"Gabapentin in comorbid anxiety and substance use","volume":"16","author":"Verduin","year":"2007","journal-title":"Am J Addict"},{"issue":"19","key":"10.1016\/j.lana.2022.100302_bib0017","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2165\/00003495-200464190-00004","article-title":"Antiepileptic drugs in the treatment of anxiety disorders: role in therapy","volume":"64","author":"Van Ameringen","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.lana.2022.100302_bib0018","article-title":"Treatment of generalized anxiety disorder with gabapentin","volume":"2017","author":"Markota","year":"2017","journal-title":"Case Rep Psychiatry"},{"issue":"3","key":"10.1016\/j.lana.2022.100302_bib0019","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1060028015620800","article-title":"Gabapentin: abuse, dependence, and withdrawal","volume":"50","author":"Mersfelder","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.lana.2022.100302_bib0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jppr.1323","article-title":"Gabapentin: a surprising drug with many uses","volume":"47","author":"Nguyen","year":"2017","journal-title":"J Pharm Pract Res"},{"issue":"8","key":"10.1016\/j.lana.2022.100302_bib0021","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","article-title":"Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the food and drug administration adverse events reporting system (FAERS)","volume":"15","author":"Evoy","year":"2019","journal-title":"Res Social Adm Pharm"},{"issue":"12","key":"10.1016\/j.lana.2022.100302_bib0022","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.lana.2022.100302_bib0023","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.apnu.2019.01.003","article-title":"The unsuspected threat of three opioid-like substitutes","volume":"33","author":"Kim","year":"2019","journal-title":"Arch Psychiatr Nurs"},{"issue":"4","key":"10.1016\/j.lana.2022.100302_bib0024","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/1556-4029.14021","article-title":"Gabapentin-related deaths: patterns of abuse and postmortem levels","volume":"64","author":"Tharp","year":"2019","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.lana.2022.100302_bib0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2018.01.018","article-title":"Prevalence of gabapentin in drug overdose postmortem toxicology testing results","volume":"186","author":"Slavova","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.lana.2022.100302_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"H\u00e4kkinen","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"2","key":"10.1016\/j.lana.2022.100302_bib0027","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-017-0595-1","article-title":"All-cause and drug-related medical events associated with overuse of gabapentin and\/or opioid medications: a retrospective cohort analysis of a commercially insured US population","volume":"41","author":"Peckham","year":"2018","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.lana.2022.100302_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.lana.2022.100302_bib0029","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/add.15189","article-title":"Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study","volume":"116","author":"Zhou","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.lana.2022.100302_bib0030","article-title":"Minimum sample size for developing a multivariable prediction model: Part II -binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.lana.2022.100302_bib0031","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/AJP.0000000000000021","article-title":"The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription","volume":"30","author":"Edlund","year":"2014","journal-title":"Clin J Pain"},{"issue":"10","key":"10.1016\/j.lana.2022.100302_bib0032","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/j.pain.0000000000001934","article-title":"Patterns of prescription opioid utilization among adolescents and adults with comorbid chronic pain and mental health diagnosis","volume":"161","author":"Olopoenia","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.lana.2022.100302_bib0033","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2147\/JPR.S144963","article-title":"Risk of respiratory depression with opioids and concomitant gabapentinoids","volume":"10","author":"Savelloni","year":"2017","journal-title":"J Pain Res"},{"issue":"No. RR-1","key":"10.1016\/j.lana.2022.100302_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC Guidelines for prescribing opioids for chronic pain\u2015United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.lana.2022.100302_bib0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.aje.a112339","article-title":"Stratification by a multivariate confounder score","volume":"104","author":"Miettinen","year":"1976","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.lana.2022.100302_bib0036","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.1845","article-title":"Confounder summary scores when comparing the effects of multiple drug exposures","volume":"19","author":"Cadarette","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.lana.2022.100302_bib0037","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/aje\/kwv269","article-title":"Performance of disease risk score matching in nested case-control studies: a simulation study","volume":"183","author":"Desai","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.lana.2022.100302_bib0038","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/aje\/kwr143","article-title":"Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders","volume":"174","author":"Arbogast","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.lana.2022.100302_bib0039","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Sclar David A. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Healthc Policy"},{"issue":"4","key":"10.1016\/j.lana.2022.100302_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2021.01.025","article-title":"Gabapentin controlled substance status","volume":"61","author":"Campbell","year":"2021","journal-title":"J Am Pharm Assoc"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X22001193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X22001193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:52:57Z","timestamp":1757404377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X22001193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":40,"alternative-id":["S2667193X22001193"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2022.100302","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: A nested case-control study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2022.100302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100302"}}